Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovations in mental health care. Their primary focus is on developing COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support, targeting treatment-resistant depression (TRD). In their phase 2b trial, a single 25mg dose of COMP360 demonstrated a statistically significant reduction in depressive symptoms after three weeks. Currently, Compass is conducting a phase 3 clinical program, the largest of its kind, to further evaluate COMP360's efficacy in TRD. Additionally, they are exploring its potential for treating post-traumatic stress disorder and anorexia nervosa. Committed to rigorous scientific research and compassionate care, Compass Pathways aims to transform mental health treatment for those unresponsive to existing therapies.